Study of HR20013 for Injection in Patients With Malignant Solid Tumors

NCT05465681 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

24

Enrollment

INDUSTRY

Sponsor class

Conditions

Prevention of Nausea and Vomiting Caused by Highly Emetogenic Chemotherapy

Interventions

DRUG: HR20013 for injection；dexamethason

Sponsor

Fujian Shengdi Pharmaceutical Co., Ltd.